Arcutis Biotherapeutics, Inc. (ARQT) Earnings Call Analysis

NASDAQ · Healthcare · Biotechnology

19/25

Growth 5 Margin 4 Expansion 4 Platform 2 Financial 4

latest quarter score

Earnings Reports

19
Arcutis (ARQT) Q2 2026: Zareve Demand Drives 59% Revenue Growth, Guidance Raised on Prescription Momentum
August 06, 2026
18
Arcutis (ARQT) Q1 2026: Zareve Captures 48% Branded Topical Share, Expanding Pediatric Reach
May 07, 2026
19
Arcutis (ARQT) Q4 2025: Zareve Captures 45% Segment Share as Non-Steroidal Topicals Displace Steroids
February 26, 2026
20
Arcutis (ARQT) Q3 2025: Zareve Net Revenue Jumps 122% as Steroid Conversion Accelerates
October 28, 2025
16
Arcutis (ARQT) Q2 2025: Zureve Franchise Drives 164% Revenue Surge as Steroid Conversion Accelerates
August 06, 2025
18
Arcutis (ARQT) Q1 2025: Zareve Scripts Jump 10% Despite Seasonal Headwinds, Underscoring Market Conversion Momentum
July 06, 2025
Arcutis (ARQT) Q3 2024: Zareev Sales Surge 452% as Non-Steroidal Topical Adoption Accelerates
November 06, 2024
Arcutis Biotherapeutics (ARQT) Q2 2024: Zareve Scripts Jump 42% as Indications Expand, Primary Care Push Builds for 2025
August 14, 2024
Arcutis (ARQT) Q1 2024: Zoryve Foam Drives 59% Sequential Revenue Jump as Portfolio Expansion Accelerates
May 14, 2024
Arcutis (ARQT) Q4 2023: Zoryve Foam Launch Drives 67% Sequential Revenue Growth, Expanding Addressable Market
February 27, 2024
14
Arcutis (ARQT) Q3 2023: Zoryve Prescribers Climb to 9,000 as Market Access Drives 70% Revenue Growth
November 03, 2023
Arcutis (ARQT) Q2 2023: 40% TRX Growth Signals Coverage Gains, Setting Up Multi-Indication Expansion
August 08, 2023
Arcutis (ARQT) Q1 2023: Zoryve Scripts Double as Coverage Expands to 110M Lives
May 09, 2023

Browse all companies